<?xml version="1.0" encoding="UTF-8"?>
<p>Adamantanes and neuraminidase inhibitors (NAIs) are the 2 classes of drugs indicated for preventing or treating influenza virus infection. In 2005, the high prevalence of influenza viruses A (H3N2) with S31N mutation in M2 limited the effectiveness of amantadine (
 <xref ref-type="bibr" rid="R1">
  <italic>1</italic>
 </xref>,
 <xref ref-type="bibr" rid="R2">
  <italic>2</italic>
 </xref>). In 2008, the emergence of subtype H1N1 with H274Y mutation in neuraminidase (NA) raised concerns about the use of oseltamivir (
 <xref ref-type="bibr" rid="R3">
  <italic>3</italic>
 </xref>,
 <xref ref-type="bibr" rid="R4">
  <italic>4</italic>
 </xref>). On the other hand, the incidence of zanamivir-resistant viruses was low (
 <xref ref-type="bibr" rid="R5">
  <italic>5</italic>
 </xref>). In 1998, 1 case of zanamivir-resistant influenza B virus, which was isolated from an immunocompromised child who underwent prolonged zanamivir treatment, was reported (
 <xref ref-type="bibr" rid="R6">
  <italic>6</italic>
 </xref>). In 2008, subtype H3N2 with D151A/V mutations in NA demonstrated reduced zanamivir sensitivity by chemiluminescent NAI assay (
 <xref ref-type="bibr" rid="R5">
  <italic>5</italic>
 </xref>). Recently, zanamivir-resistant subtype H1N1 isolates with a novel Q136K mutation in NA were isolated in Oceania and Southeast Asia (
 <xref ref-type="bibr" rid="R7">
  <italic>7</italic>
 </xref>).
</p>
